Worth reading
21Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
3000
Hundreds of millions of yenWording
Avoiding a definitive answer
How definitive the wording is.This transaction
Bridge loan agreement for additional investment in ViiV Healthcare Ltd.CounterpartySumitomo Mitsui Banking Corporation
Disclosing companyShionogi & Co.,Ltd.
TimelineThe spacing between the points is proportional to the actual number of days.
Consideration and expenses
Funding arrangementsBorrowing under a bridge loan from Sumitomo Mitsui Banking Corporation (¥300 billion)
Impact on Business Performance
The impact on the consolidated earnings forecast for the fiscal year ending March 2026 is immaterial. The impact on the consolidated earnings forecast for the fiscal year ending March 2027 is currently under review.
| Item | Details |
|---|---|
| Transaction name | Bridge loan agreement for additional investment in ViiV Healthcare Ltd. |
| Counterparty name | Sumitomo Mitsui Banking Corporation |
| Name of the Subject Company | ViiV Healthcare Ltd. |
| Funding arrangements | Borrowing under a bridge loan from Sumitomo Mitsui Banking Corporation (¥300 billion) |
| Impact on Business Performance | The impact on the consolidated earnings forecast for the fiscal year ending March 2026 is immaterial. The impact on the consolidated earnings forecast for the fiscal year ending March 2027 is currently under review. |
| Contract Date | 27 March 2026 |
| Execution Date / Effective Date | 31 March 2026 (borrowing execution date) |
Items this document does not state (25)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageGoodwill amountAmount of extraordinary income (loss)Date of board resolutionValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To raise funds for an additional investment in ViiV Healthcare Ltd. The funds raised are scheduled to be refinanced with medium- to long-term funds by the repayment date.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.